220 results about "Amyloidogenic Proteins" patented technology

The invention provides a soybean amyloid protein fiber, a preparation method thereof, a high internal phase emulsion and application, and belongs to the technical field of protein fibers. The preparation method comprises the following steps: dissolving soybean protein isolate in water, adjusting the obtained soybean protein isolate solution to a first pH value, carrying out ultrasonic treatment and / or first stirring treatment, adjusting the obtained feed liquid to a second pH value, sequentially carrying out second stirring treatment, dialysis and freeze drying, and dissolving the obtained pretreated soybean protein isolate in water, adjusting the pH value of the pretreated soybean protein isolate solution to a third pH value, and sequentially performing hydration treatment and fiber growth treatment to obtain the soybean amyloid protein fiber. The invention provides a soybean amyloid protein fiber preparation method based on ultrasonic pretreatment and / or pH migration pretreatment. The yield and the emulsifying property of the obtained soybean amyloid protein fiber can be remarkably improved.

The invention relates to the technical field of biological medicines, and particularly discloses a BODIPY (boron dipyrromethene)-based compound and an application of the BODIPY-based compound in photodynamic oxidation of beta-amyloid protein (Abeta). The compound takes iodo-BODIPY as a photosensitive core and is connected with 4-t-butyloxycarboryl benzene as an A beta recognition group. The introduction of iodine atoms significantly enhances the intersystem crossing ability of molecules, so that the molecules have excellent reactive oxygen species (ROS) generation ability. The compound has high ROS yield, good optical stability and biocompatibility, can specifically target A beta aggregate, realizes photodynamic oxidative degradation, and provides a novel potential tool for treatment of Alzheimer's disease.

The invention discloses an amyloid-like protein mediated long-acting metal organic framework antifouling agent as well as a preparation method and application thereof. Belongs to the field of marine antifouling material preparation. The anti-fouling agent is based on MOF with an anti-fouling function, and amyloid-like protein is self-assembled on the surface of the MOF to form a compact protective shell layer. According to the preparation method, metal ions and organic ligands react and are connected through coordinate bonds to form an MOF structure, and MOF particles are obtained through centrifugation, collection, precipitation, washing and drying; under the action of a water-soluble organic reducing substance, the protein completely opens a disulfide bond to form an unfolded protein chain, and the protein chain is self-assembled to obtain an amyloid-like protein solution; and placing the MOF particles in an amyloid-like protein solution, and carrying out simple one-step incubation to obtain the amyloid-like protein mediated long-acting metal organic framework antifouling agent. The antifouling agent is prepared by adopting a novel green, high-stability, rapid and efficient mild modification method, and has the advantages of stability, durability, universality and high efficiency.

The invention discloses a protein / polyphenol composite nanofiltration membrane and application thereof, and belongs to the technical field of protein membrane separation. The nano-filtration membrane is formed by modifying an amyloid-like protein film with the thickness of 50-300 nm and the average pore size of 0.4-1 nm by polyphenol and then adhering the amyloid-like protein film to a porous base material, wherein the amyloid-like protein film is formed by unfolding and self-assembling protein under the action of a modifier. The nanofiltration membrane disclosed by the invention can realize efficient selective separation of Mg < 2 + > / Li < + > in salt lake brine with a high magnesium-lithium ratio, has selective separation capacity on mixed anions Cl <-> / SO4 < 2->, can effectively remove heavy metal ions and perfluoro / polyfluoroalkyl compounds in water, and provides an important basis for developing a sustainable and high-performance next-generation membrane separation technology.

The invention belongs to the technical field of microorganisms, and relates to lactobacillus acidophilus LA4 and application thereof. The classification name of the lactobacillus acidophilus LA4 is lactobacillus acidophilus, the lactobacillus acidophilus LA4 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 9, 2025, and the preservation number of the lactobacillus acidophilus LA4 is CGMCC No.35144; the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can significantly improve cognitive impairment of an elderly behavior cognitive impairment model mouse and enhance the learning and memory ability of the mouse by reducing deposition of beta amyloid protein in the brain of the mouse, inhibiting the activity of acetylcholin esterase, regulating and controlling the neurotransmitter level, relieving brain inflammatory response, reducing nerve injury, promoting synaptic regeneration and the like. The strain provided by the invention provides a potential treatment scheme for preventing or improving senile behavioral cognitive impairment, and has important development and application values.

The present invention relates to an artificial intelligence-based device and method for determining amyloid PET positivity, wherein a normal-appearing white matter dominance ratio is used and amyloid PET positivity is automatically determined based on machine learning, thereby improving the accuracy and sensitivity of amyloid PET positivity determination. The device comprises: an image acquisition unit for acquiring PET and MRI images of the brain of a diagnostic subject administered with a contrast agent, the images being acquired through tomographic scanning; a segmentation unit for segmenting normal-appearing white matter (NAWM) and white matter hyperintensity (WMH) from a fluid attenuated inversion recovery (FLAIR) image obtained from the MRI image; a standardized uptake value ratio (SUVR) calculation unit for calculating a global standardized uptake value ratio (SUVR) and a standardized uptake value ratio in normal-appearing white matter (NAWM SUVR), on the basis of the PET image and the NAWM region segmented by the segmentation unit; and an amyloid PET positivity determination unit for determining amyloid PET positivity by inputting the global SUVR and the NAWM dominance ratio (NDR) into a pre-trained prediction model, wherein the NDR is a value obtained by dividing the global SUVR by the NAWM SUVR.

The invention discloses a silent pituitary ACTH cytoma identification method. The method comprises the following steps: determining a pituitary neuroendocrine tumor through imaging examination; a serum marker SAA (serum amyloid protein A) index is obtained through blood detection; constructing a silent pituitary ACTH cytoma recognition model by combining serum marker SAA indexes, age, gender, clinical symptoms and various hormone variable characteristics of pituitary; and identifying and judging the silent pituitary ACTH cytoma according to the identification model. The serum SAA is used as an index for identifying the silent pituitary ACTH cytoma, and the serum SAA is used as a mature serum detection index in clinical application, so that a doctor can accurately identify a high-risk subtype of the silent pituitary ACTH cytoma which is a pituitary neuroendocrine tumor, and can adjust an operation strategy according to factors such as invasiveness and recurrence risk of the tumor; therefore, the operation effect is improved, and patient prognosis is improved.

The invention belongs to the technical field of biochemistry, and discloses a chemiluminescent probe responding to beta amyloid protein as well as a preparation method and application thereof. The structural formula of the probe is shown in the specification. According to the probe designed by the invention, the near-infrared chemiluminescence capability (gt; 650nm) is realized through an extended conjugated structure; meanwhile, high selectivity on A beta is realized by introducing a heteroatom conjugate pi bridge.

The application provides a plant amyloid protein fiber and a preparation method and a composite film and a composite coating film preservative thereof, and belongs to the technical field of protein fibers. Plant protein isolate is mixed with water, and after the pH value is adjusted to 1.5-2.5, solid-liquid separation is carried out, the obtained plant protein-containing liquid material is subjected to fiber growth treatment, and a plant amyloid protein fiber is obtained. According to the growth kinetics curve, the fiber growth treatment comprises sequentially performing first incubation treatment, ultrasonic treatment and second incubation treatment, the time of the first incubation treatment is 0 h-end of the logarithmic growth phase, and the first incubation treatment and the second incubation treatment are performed under non-ultrasonic conditions. When the time of the first incubation treatment is 0 h, the ultrasonic power density of the ultrasonic treatment is greater than or equal to 2.5 W / mL. The method is convenient for simultaneously regulating the growth process and morphology of the fiber, and can reduce the proportion of rigid fibers.

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.

The present invention relates to a cell-penetrating peptide and its derivatives to inhibit α-synuclein fibrillation. The present invention specifically relates to a peptide-based inhibitor of Parkinson's Disease. The present invention discloses the identification of the peptides permeable to blood brain barrier for inhibition. α-synuclein fibril formation is observed in the presence of peptides as indicated by SEQ. ID-7, SEQ. ID-8 wherein the SEQ. ID-7, SEQ. ID-8 are truncated versions of SEQ. ID-4 having the homology of 83% and 75% respectively. It provides a peptide having an amino acid sequence of Formula 1. The present invention also provides a pharmaceutical composition comprising a peptide of Formula 1 along with the pharmaceutically acceptable excipient(s) having inhibitory activity against β-sheet polymerisation of amyloidogenic proteins. The analysis showed that peptides corresponding to SEQ. ID-7, SEQ. ID-8 are better inhibitors than SEQ. ID-4 against α-synuclein fibrillation.

The present invention discloses a β-amyloid protein probe and a preparation method and application thereof. The skeleton of the β-amyloid protein probe can effectively increase the ICT effect of the probe, so that the probe has a larger emission wavelength and a larger fluorescence intensity enhancement factor before and after binding to the Aβ protein. At the same time, it uses a nitrogen-containing six-membered aromatic ring as an electron acceptor, which not only has better electron-withdrawing ability, but also the large steric hindrance of the electron acceptor after the probe enters the hydrophobic cavity of the Aβ protein can strengthen the restriction on molecular torsion, and trigger a more efficient ICT effect with the thiophene-containing π bridge. At the same time, this type of nitrogen-containing six-membered aromatic ring can combine well with the β-sheet structure of the Aβ protein, effectively improving the binding ability of the probe to the Aβ protein and the Aβ protein selectivity. Therefore, the probe can be used for labeling Aβ protein and preparing an imaging agent for labeling Aβ protein.

Compounds, systems, kits, methods, and / or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and / or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and / or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.

The present disclosure provides anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that preferentially bind to soluble amyloid [beta] fibrils / oligomers and trigger ADPC in microglial cells; anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that reduce soluble amyloid [beta] fibril / oligomer levels and insoluble amyloid [beta] plaques in brain tissue; and the use of anti-A [beta] fibril / oligomer antibodies and antibody fragments in the treatment, prevention, diagnosis, screening and monitoring of conditions associated with A [beta] protein aggregation, in particular Alzheimer's Disease (AD).

Disclosed are an amyloid β measurement method and a reagent capable of more accurately measuring amyloid β and unaffected by molecular target drugs (antibody drugs) for amyloid β. Provided is an immunoassay method for amyloid β in a sample isolated from a living body including a pretreatment step for mixing a sample isolated from a living body, (1) an acidifying agent, and (2) at least one selected from the group consisting of cationic surfactants, zwitterionic surfactants, protein denaturants, and chelating agents.

Provided is a pharmaceutical combination for preventing or treating a neurodegenerative disease. The pharmaceutical combination includes a first agent being an insulin sensitizer and a second agent being a lipid metabolism modulator. Also provided is a method for preventing or treating a neurodegenerative disease in a subject in need thereof by administering the first agent and the second agent to the subject, thereby reducing the visceral adiposity and the accumulation of amyloid β peptides in the subject.

Provided herein are antibodies that selectively bind N3pGlu Amyloid Beta peptide and their use in treating conditions or diseases characterized by deposition of Amyloid Beta.

To provide a novel amyloid beta (A beta) binding molecule, especially an amyloid beta antibody or an antigen-binding fragment thereof, and / or use of them.SOLUTION: There is provided an amyloid beta binding antibody including: VH-CDR1 including a specific amino acid sequence, VH-CDR2 including a specific amino acid sequence, VH-CDR3 including a specific amino acid sequence, VL-CDR1 including a specific amino acid sequence, VL-CDR2 including a specific amino acid sequence, and VL-CDR3 including a specific amino acid sequence; or an antigen-binding fragment thereof. In one embodiment, independently of an amyloid beta peptide or a three-dimensional structure states of a seed, an amyloid beta binding antibody or an antigen binding fragment thereof selectively binds to an amyloid beta peptide or seed in a solution, or captures the amyloid beta peptide or seed.SELECTED DRAWING: None

The present invention relates to the field of biomedicine technology, and specifically discloses a dicyanoisophorone fluorescent probe for detecting brain β-amyloid protein, its preparation method and application. The fluorescent probe of the present invention is based on the dicyanoisophorone structure, and a probe with dual recognition sites is formed by introducing a carbamate group and an N,N-dimethylamino group. Compared with probes with a single recognition site, probes with dual recognition sites have a more sensitive fluorescent response to Aβ aggregates in vitro and show higher binding affinity and selectivity. The probe can effectively cross the blood-brain barrier and show high reactivity in the brains of Alzheimer's disease model mice. In addition, the probe can monitor the Aβ levels in the brains of Alzheimer's disease mice of different ages. It has great potential in the early diagnosis of neurodegenerative diseases.

The invention belongs to the technical field of protein removal, and discloses an Alzheimer's disease beta amyloid protein removal system which comprises a cross-blood-brain barrier delivery module, an A beta specific recognition module, an immune regulation module and a degradation and metabolism module. According to the combined type A beta removal system, through multi-module integration, the synergistic treatment effects of efficient blood brain barrier crossing, accurate focus recognition, rapid A beta hydrolysis and inflammation control are achieved. The system can significantly reduce the pathological burden of the Alzheimer's disease, delays cognitive function degradation, and shows more significant technical progress and application prospects compared with the existing single antibody or enzyme scavenger.

The present application provides methods, compositions and kits for determining SHD-catalyzed antibody levels in a biological sample and for treating or preventing protein aggregation disease (PAD) in an individual. Catalytic antibodies that specifically recognize amyloid beta (A beta) peptides and methods of using the same are also provided.

The invention discloses a chitosan / lysozyme amyloid protein fiber composite microneedle based on ethephon controlled release and application of the composite microneedle in on-demand ripening acceleration of harvested fruits, and belongs to the technical field of agricultural product after-harvest treatment. The composite microneedle is composed of chitosan, lysozyme amyloid protein fibers and ethephon, the mass ratio of the chitosan to the lysozyme amyloid protein fibers is 5: 5, and the ethephon loading capacity is that 131.13 [mu] L of a 40% ethephon solution is added to every 17.5 mL of a 1% chitosan solution. The microneedle can be inserted into the epidermis of picked fruits to realize on-demand slow release of ethephon and promote ripening of the fruits, meanwhile, the lysozyme amyloid protein fiber provides an antibacterial effect, the aging process of the fruits after ripening is effectively delayed, the infection rate of colletotrichum gloeosporioides is reduced, and the ethephon residue in the fruits is remarkably lower than the national limited standard. The method solves the problems of non-uniform fruit ripening, excessive softening and potential toxicity caused by a traditional ethephon ripening method, and realizes integration of batch on-demand ripening and preservation of picked fruits.

The invention relates to a method for screening an anti-Alzheimer's disease compound based on a high content imaging technology, and the method comprises the following steps: S1, carrying out splitting decomposition and centrifugation on nematodes to remove a supernatant, and then carrying out resuspension culture to obtain a synchronized nematode solution in an L1 period, the nematodes carrying a human-derived beta amyloid protein gene connected in series with a fluorescent protein gene; s2, adding a synchronized nematode solution in the L1 period to an NGM solid culture medium paved with a candidate anti-Alzheimer's disease compound, culturing to the L4 period, collecting nematodes, adding an OP50 bacterial solution, and inducing human beta amyloid protein gene expression; s3, collecting nematodes for inducing human beta amyloid protein gene expression, and performing fluorescence image shooting by using a high content imaging technology; and S4, analyzing the fluorescence intensity in the picture. Compared with the prior art, the high-content imaging technology is adopted, the defects that a traditional A beta fluorescence detection method in a CL2331 nematode model is low in efficiency and long in consumed time are overcome, the detection sensitivity is improved by 27.63%, and the efficiency is improved by 40 times.

This disclosure describes compositions including dimethylglyoxime (DMG) and methods of using those compositions including, for example, to reduce the availability of nickel in the subject. In some aspects, the composition may be administered to a subject suffering from or susceptible to a bacterial infection and / or to a subject suffering from or susceptible to a amyloid-β peptide aggregation. In some aspects, this disclosure describes using DMG or a composition including DMG to disrupt a biofilm or reduce the likelihood of biofilm formation.

The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the compound N-acetylcysteine or a derivative thereof to support cognitive health in a subject that takes the product or combination product. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system as well as the treatment of disease and conditions that are acerbated by free radicals.

The present application relates to the technical field of immunochromatography, and in particular, to a test strip for detecting β-amyloid protein and the use thereof. In the present application, colored microspheres are conjugated to a β-amyloid monoclonal antibody via covalent bonds, and then the conjugate is coated onto a conjugate pad. Compared with colloidal gold, the colored microspheres exhibit greater stability and higher sensitivity. Additionally, the colored microspheres feature bright and diverse colors, uniform particle sizes, good monodispersity, and strong reproducibility of detection results. The test strip provided by the present application has the advantages of simplicity, rapidity and high timeliness, requires no additional reagents, instruments and professional personnel, and supports on-site operation. By means of simply applying a to-be-detected sample to a sample loading port of the test strip, a detection result can be interpreted within 15 min. The result interpretation is visual, intuitive, accurate and straightforward, with a low risk of human errors such as false positives and false negatives.

The invention relates to the technical field of food preservation, in particular to hydrogel containing an electric field response antibacterial material as well as a preparation method and application of the hydrogel. The hydrogel is prepared from the following raw materials in parts by weight: 0.1 to 0.2 part of an electric field response antibacterial material; 2-5 parts by weight of polyvinyl alcohol; 0.5-3 parts by weight of amyloid protein fiber; 30-40 parts by weight of glycerin; and 0.3-0.5 part by weight of sodium chloride. The electric field response antibacterial hydrogel prepared by the invention has the capability of generating active oxygen such as superoxide anions, singlet oxygen and hydroxyl radicals, and has a good in-vitro antibacterial effect on aquatic product putrefying bacteria (shewanella putrefaciens).

The invention provides a method of detecting renal cancer mark- ers in a biological sample from a patient suspected of or to be evaluated for having renal cancer, comprising detecting one or more marker proteins selected from Lipocalin 15, Serum amyloid A1, and Haptoglobin, in the biological sample. The invention further provides a kit suitable for use with the inventive method.

Provided herein is a method of detecting an amyloid peptide in a patient sample, including exposing the patient sample to a binding reagent in the presence of an assay binding buffer, thereby immunoprecipitating the amyloid peptide; washing the immunoprecipitated amyloid peptide; eluting the washed, immunoprecipitated amyloid peptide, thereby generating free amyloid peptide; and analyzing the free amyloid peptide with a mass spectrometer.